The 5 constituents in the Psychedelic Drug Stocks Index jumped 30.2% in November, on average, and were up a further 2.8% last week but remain down 10.1% YTD, on average.Below is how they performed, in descending order, with pertinent news.
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- Read: atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- Read: Compass Pathways PLC Stock Forecast
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
- Read: Incannex Healthcare Announces Completion of its Re-domiciliation to the United States
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- Read: MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- Read: GH Research Stock Forecast & Price Target
Summary
The Psychedelic Drug Stocks Index was down 14.3% in August, down another 14.2% in September and down 27.3% in October but was up 30.2% in November and was up another 2.8% last week but is still down 10.1% YTD. The AdvisorShares Psychedelic ETF (), in comparison, was up 2.3% and remains down 28.5% YTD.More By This Author:
